Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia.

Riedel SS, Haladyna JN, Bezzant M, Stevens B, Pollyea DA, Sinha AU, Armstrong SA, Wei Q, Pollock RM, Daigle SR, Jordan CT, Ernst P, Neff T, Bernt KM.

J Clin Invest. 2016 Apr 1;126(4):1438-50. doi: 10.1172/JCI80825. Epub 2016 Feb 29.

2.

MLL-AF9- and HOXA9-mediated acute myeloid leukemia stem cell self-renewal requires JMJD1C.

Zhu N, Chen M, Eng R, DeJong J, Sinha AU, Rahnamay NF, Koche R, Al-Shahrour F, Minehart JC, Chen CW, Deshpande AJ, Xu H, Chu SH, Ebert BL, Roeder RG, Armstrong SA.

J Clin Invest. 2016 Mar 1;126(3):997-1011. doi: 10.1172/JCI82978. Epub 2016 Feb 15.

3.

DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.

Chen CW, Koche RP, Sinha AU, Deshpande AJ, Zhu N, Eng R, Doench JG, Xu H, Chu SH, Qi J, Wang X, Delaney C, Bernt KM, Root DE, Hahn WC, Bradner JE, Armstrong SA.

Nat Med. 2015 Apr;21(4):335-43. doi: 10.1038/nm.3832. Epub 2015 Mar 30.

4.

AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes.

Deshpande AJ, Deshpande A, Sinha AU, Chen L, Chang J, Cihan A, Fazio M, Chen CW, Zhu N, Koche R, Dzhekieva L, Ibáñez G, Dias S, Banka D, Krivtsov A, Luo M, Roeder RG, Bradner JE, Bernt KM, Armstrong SA.

Cancer Cell. 2014 Dec 8;26(6):896-908. doi: 10.1016/j.ccell.2014.10.009. Epub 2014 Nov 20.

5.

Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia.

Mar BG, Bullinger LB, McLean KM, Grauman PV, Harris MH, Stevenson K, Neuberg DS, Sinha AU, Sallan SE, Silverman LB, Kung AL, Lo Nigro L, Ebert BL, Armstrong SA.

Nat Commun. 2014 Mar 24;5:3469. doi: 10.1038/ncomms4469.

6.

Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.

Deshpande AJ, Chen L, Fazio M, Sinha AU, Bernt KM, Banka D, Dias S, Chang J, Olhava EJ, Daigle SR, Richon VM, Pollock RM, Armstrong SA.

Blood. 2013 Mar 28;121(13):2533-41. doi: 10.1182/blood-2012-11-465120. Epub 2013 Jan 29.

7.

Cell of origin determines clinically relevant subtypes of MLL-rearranged AML.

Krivtsov AV, Figueroa ME, Sinha AU, Stubbs MC, Feng Z, Valk PJ, Delwel R, Döhner K, Bullinger L, Kung AL, Melnick AM, Armstrong SA.

Leukemia. 2013 Apr;27(4):852-60. doi: 10.1038/leu.2012.363. Epub 2012 Dec 13.

8.

mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis.

Kalaitzidis D, Sykes SM, Wang Z, Punt N, Tang Y, Ragu C, Sinha AU, Lane SW, Souza AL, Clish CB, Anastasiou D, Gilliland DG, Scadden DT, Guertin DA, Armstrong SA.

Cell Stem Cell. 2012 Sep 7;11(3):429-39. doi: 10.1016/j.stem.2012.06.009.

9.

Polycomb repressive complex 2 is required for MLL-AF9 leukemia.

Neff T, Sinha AU, Kluk MJ, Zhu N, Khattab MH, Stein L, Xie H, Orkin SH, Armstrong SA.

Proc Natl Acad Sci U S A. 2012 Mar 27;109(13):5028-33. doi: 10.1073/pnas.1202258109. Epub 2012 Mar 6.

10.

iCanPlot: visual exploration of high-throughput omics data using interactive Canvas plotting.

Sinha AU, Armstrong SA.

PLoS One. 2012;7(2):e31690. doi: 10.1371/journal.pone.0031690. Epub 2012 Feb 29.

11.

Chromatin-modifying enzymes as modulators of reprogramming.

Onder TT, Kara N, Cherry A, Sinha AU, Zhu N, Bernt KM, Cahan P, Marcarci BO, Unternaehrer J, Gupta PB, Lander ES, Armstrong SA, Daley GQ.

Nature. 2012 Mar 4;483(7391):598-602. doi: 10.1038/nature10953.

12.

Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains.

Trowbridge JJ, Sinha AU, Zhu N, Li M, Armstrong SA, Orkin SH.

Genes Dev. 2012 Feb 15;26(4):344-9. doi: 10.1101/gad.184341.111.

13.

eXframe: reusable framework for storage, analysis and visualization of genomics experiments.

Sinha AU, Merrill E, Armstrong SA, Clark TW, Das S.

BMC Bioinformatics. 2011 Nov 21;12:452. doi: 10.1186/1471-2105-12-452.

14.

MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.

Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV, Feng Z, Punt N, Daigle A, Bullinger L, Pollock RM, Richon VM, Kung AL, Armstrong SA.

Cancer Cell. 2011 Jul 12;20(1):66-78. doi: 10.1016/j.ccr.2011.06.010.

15.

The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML.

Wang Y, Krivtsov AV, Sinha AU, North TE, Goessling W, Feng Z, Zon LI, Armstrong SA.

Science. 2010 Mar 26;327(5973):1650-3. doi: 10.1126/science.1186624.

16.

MLL-rearranged B lymphoblastic leukemias selectively express the immunoregulatory carbohydrate-binding protein galectin-1.

Juszczynski P, Rodig SJ, Ouyang J, O'Donnell E, Takeyama K, Mlynarski W, Mycko K, Szczepanski T, Gaworczyk A, Krivtsov A, Faber J, Sinha AU, Rabinovich GA, Armstrong SA, Kutok JL, Shipp MA.

Clin Cancer Res. 2010 Apr 1;16(7):2122-30. doi: 10.1158/1078-0432.CCR-09-2765. Epub 2010 Mar 23.

17.

H3K79 methylation profiles define murine and human MLL-AF4 leukemias.

Krivtsov AV, Feng Z, Lemieux ME, Faber J, Vempati S, Sinha AU, Xia X, Jesneck J, Bracken AP, Silverman LB, Kutok JL, Kung AL, Armstrong SA.

Cancer Cell. 2008 Nov 4;14(5):355-68. doi: 10.1016/j.ccr.2008.10.001.

18.

Dissecting microregulation of a master regulatory network.

Sinha AU, Kaimal V, Chen J, Jegga AG.

BMC Genomics. 2008 Feb 23;9:88. doi: 10.1186/1471-2164-9-88.

19.
20.

Supplemental Content

Loading ...
Support Center